An observational study in Kidney Diseases, Kidney Transplant Failure and Rejection and Urinary Tract Infections, sponsored by Royal Free Hospital NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-14.
Sponsored by Royal Free Hospital NHS Foundation Trust · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies in Kidney Diseases with a site in United Kingdom — 13 open to participants now, 25 under way, 10 of them phase 3. Kidney Diseases · United Kingdom.
Among the 63 studies in Kidney Diseases with a site in United Kingdom, this one is the 7th largest by planned enrollment of the 16 observational ones that give a count, is one of 4 that started in 2020, is one of 16 observational ones, reaches primary completion later than 5 of the 24 other live ones, and was the 35th registered.
970 studies on the registry are indexed under Kidney Diseases; 185 are open to participants now.
Browse Kidney Diseases studies →13 of the 63 studies in Kidney Diseases with a site in United Kingdom are open now. Recruiting first, the newest first:
LumiraDx UK Limited · Sites in United Kingdom
Ages 16+
Purespring Therapeutics Limited · Sites in United Kingdom, United States
Ages 18+
Eli Lilly and Company · Sites in United Kingdom, Argentina, Australia and 35 more countries
Ages 50+
Takeda · Sites in United Kingdom, Belgium, Estonia and 4 more countries
Ages 18+
Biohaven Therapeutics Ltd. · Sites in United Kingdom, United States
Ages 18–65
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 131 Kidney Diseases studies recruiting now, 77 (59%) set no upper age limit and 34 (26%) stop at 75 or younger; 27 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 14 · Phase 3 18 · Phase 4 2
First in 2001; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 130 is below the median of 246 across 278 observational studies indexed under Kidney Diseases.
Median enrollment 86 across the 47 interventional studies, 122 across the 16 observational. Of the 33 that completed or were terminated, 14 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 63 have an industry lead sponsor. The 10 most frequent:
Royal Free Hospital NHS Foundation Trust is the lead sponsor of 34 studies on the registry; 8 are open to participants now.
Royal Free Hospital NHS Foundation Trust has 1 study filed under Kidney Diseases — fewer than ten, so there is no comparison to draw.
7 of the studies in Kidney Diseases with a site in United Kingdom that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04020055Phase 3Amicus TherapeuticsA Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease | 2026-12-31 |
| NCT06087835Phase 3AstraZenecaStudy to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) | 2027-02-18 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT06243731TakedaA Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation | 2027-01-31 |
| NCT06147232Steno Diabetes Center CopenhagenPrevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxia | 2027-05 |
Add all 7 to your calendar (.ics) → With an account.
Among the 63 studies in Kidney Diseases with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The human gastrointestinal tract harbours \~40 trillion microbial cells, far outnumbering the cell number, and therefore the genetic content of its host. How this genetically diverse bacterial (collectively referred as 'microbiota') co-resident modulates host homeostasis is largely unknown. We are increasing gaining a better understanding how the microbes modulate mucosal and systemic metabolic/immune and organ systems including the kidney, heart and the brain. Therapeutic targeting of the gastrointestinal (GI) microbiota may help improve clinical outcomes in conditions as diverse as arthritis, cardiovascular disease, and cancer. In contrast to other organ systems, studies investigating the role of the microbiota in modulating clinical outcomes in renal transplantation lags behind.
The aim of the study is to examine (a) how alterations in the urinary and GI microbiota and associated metabolites impact on host immunity after renal transplantation, and (b) whether such changes are correlated with post-transplant complications, such as rejection, development of de novo donor specific antibodies, metabolic complications (e.g post-transplant diabetes) and infections. Participants will be followed before and up to twelve months post-transplantation, and, longitudinal microbial data will be correlated with in-depth immune phenotyping and clinical end-points to define the impact that changes in urinary and GI microbial ecology have on kidney transplant outcomes.
Renal transplant live-donors and recipients of live-donor and cadaveric renal transplants
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All adult (≥18 years old) undergoing living donor nephrectomy or kidney transplantation. Patients willing to provide samples including Urine, Blood, Faecal samples.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants that will be a planned live renal transplant donor
Other: Pre-operative assessment - blood, urine, & faecal sample · Other: Post-operative day 3 assessment - blood, urine, & faecal sample · Other: Post-operative week 4-6 assessment - blood, urine, & faecal sample · Other: Post-operative 3 month assessment - blood, urine, & faecal sample · Other: Pre-operative 6 month assessment - blood, urine, & faecal sample · Other: Post-operative month 12 recipient assessment - blood, urine, & faecal sample
Renal transplant recipient on the waiting list to have or will have had an ABO-blood group compatible live-donor or cadaveric transplant
Other: Pre-operative assessment - blood, urine, & faecal sample · Other: Post-operative week 4-6 assessment - blood, urine, & faecal sample · Other: Post-operative 3 month assessment - blood, urine, & faecal sample · Other: Pre-operative 6 month assessment - blood, urine, & faecal sample · Other: Post-operative month 12 recipient assessment - blood, urine, & faecal sample
Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature. Urine and faecal samples for 16S rRNA gene sequencing
Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature. Urine and faecal samples for 16S rRNA gene sequencing.
Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature. Urine and faecal samples for 16S rRNA gene sequencing.
Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature. Urine and faecal samples for 16S rRNA gene sequencing.
Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature. Urine and faecal samples for 16S rRNA gene sequencing.
Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature. Urine and faecal samples for 16S rRNA gene sequencing.
Change in gastrointestinal and urinary microbiota composition and diversity
To understand the overall impact of transplantation on changes to the urinary and GI microbiota, the relative abundance of bacterial taxa will be evaluated using 16S rRNA gene sequencing methodologies. Alpha and Beta diversity indices will be determined from urine samples and faecal samples before and after live-donation and transplantation.
Time frame: 1 year
Correlation of change in gastrointestinal and urinary microbiota diversity with post-transplantation outcomes.
Incidence of renal graft dysfunction will be determined by the Modification of Diet in Renal Disease (MDRD)-derived estimated Glomerular Filtration Rate (eGFR) at 12 months. Graft survival time - date of transplantation to date of irreversible graft failure signified by return to dialysis (or re-transplantation, whichever is earlier) or the date of last follow-up during the period when the transplant was still functioning. In the event of death with a functioning graft, the follow-up period will be censored at the date of death.
Time frame: 1 year
Change in frequency of conventional and regulatory immune phenotypes and correlation with clinical outcome and microbial diversity changes
A panel of validated immune monitoring assays (including multi-colour flow cytometry, intracellular cytokine staining, enzyme-linked immune absorbent spot \[ELISpot\], enzyme-linked immunosorbent assay \[ELISA\] and transcriptional analysis) will be used to analyse immunological parameters in patient samples.
Time frame: 1 year
Change in microbial-associated metabolite profile and correlation with clinical outcomes and/or microbial diversity changes
A combination of 1H nuclear magnetic resonance (NMR) spectroscopy and liquid chromatography-mass spectrometry will be used to measure the metabolic phenotype of urine and faecal samples from transplant donors and recipients (pre-operatively and up to 12 months after surgery).
Time frame: 1 year
Incidence of renal graft dysfunction as determined by the MDRD-derived estimated Glomerular Filtration Rate (eGFR).
A significant deterioration in graft dysfunction is defined as the percent of patients exhibiting an eGFR \<45 mL/min/1.73m2 at month 12 or a decrease in eGFR ≥10 mL/min/1.73m2 from month 3 to month 12 after transplantation.
Time frame: 1 year
The proportion of patients reaching a defined CKD stage at up to 5 years after transplantation.
Defined by the kidney disease outcomes quality initiative for CKD stages, with eGFR \<30 mL/min/1.73m2 considered to be advanced renal dysfunction.
Time frame: 5 years
Incidence of biopsy proven acute or chronic cellular or humoral rejection up to 5 years after transplantation as per Banff classification
Revised Banff 2017 classification of antibody-mediated rejection and T cell-mediated rejection in renal allografts.
Time frame: 5 years
Incidence of post-donation and post-transplant bacterial or viral infections up to 5 years after surgery
Infectious complications will include, but not be limited to, urinary tract infections (defined as a positive urine culture \[\>50,000 CFUs/ml\] from mid-stream urine, and categorised as asymptomatic bacteriuria \[no symptoms\], cystitis \[lower urinary tract symptoms without systemic features\] or pyelonephritis \[systemic features, graft dysfunction, CRP\>50\]), BK viraemia, cytomegalovirus (CMV) viraemia, and respiratory tract (RV) infections.
Time frame: 5 years
Patient and graft survival rates up to 5 years after transplantation.
Graft survival time will be calculated from the date of transplantation to the date of irreversible graft failure signified by return to dialysis (or re-transplantation, whichever is earlier) or the date of last follow-up during the period when the transplant was still functioning. In the event of death with a functioning graft, the follow-up period will be censored at the date of death.
Time frame: 5 years
PDFs hosted by the registry, ClinicalTrials.gov.
Started Mar 2020 (actual). Primary completion is estimated for Jun 2025, 63 months after the start.
Of 100 non-industry observational studies under Kidney Diseases, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 33. This study's planned 63 months is close to that.
Counting every sponsor, half of 117 studies reached it within 59 months; a quarter within 31 and three quarters within 118.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Royal Free Hospital NHS Foundation Trust